Factory Supply Pharmaceutical Raw Material Omeprazole Powder CAS 73590-58-6 with 99% Purity

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >98%
• Model NO.: Omeprazole
• Product Name: Omeprazole
• CAS No.: 73590-58-6
• Molecular Formula: C17H19N3O3S
• Molecular Weight: 345.42
• Melting Point: 156°C
• Boiling Point: 600.0±60.0 °C(Predicted)
• Density: 1.332 g/cm3
• Transport Package: Foil Bag
• Specification: 1kg /bag
• Trademark: SENWAYER
• Origin: China
• HS Code: 29333990
• Production Capacity: 1000kg/Month

Product Description

 Factory Supply Pharmaceutical Raw Material Omeprazole Powder CAS 73590-58-6 with 99% Purity

Product name	Omeprazole
CAS number	73590-58-6
Molecular formula	C17H19N3O3S
Molecular weight	345.42

Appearance	White Powder
Purity	99.0%
Description	Omeprazole is a commonly used gastric acid inhibitor in digestive department. It belongs to proton pump inhibitor. It can inhibit hydrogen potassium ATPase on gastric parietal cells, effectively inhibit gastric acid secretion and improve gastric juice pH.

 

 

Omeprazole(Prilosec) is a proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome. Omeprazole virtually eliminated intragastric acidity in all patients: the median 24 hour intragastric pH rose from 1.4 to 5.3 and the mean hourly hydrogen ion activity fell from 38.50 to 1.95 mmol(mEq)/1 (p less than 0.001). This inhibition of 24 hour intragastric acidity is more profound than that previously reported with either cimetidine 1 g daily or ranitidine 300 mg daily.
The pharmacokinetics of omeprazole were studied in a group of healthy male subjects after single and repeated oral doses of 30 and 60 mg. Absorption of omeprazole from its enteric-coated formulation was unpredictable. There was a highly significant increase in the area under the plasma concentration time curve (AUC) after repeated dosing. Omeprazole increases its own relative availability following repeated dosing. This may be due to inhibition of gastric acid secretion by omeprazole which is an acid-labile compound.Clinical indications: Duodenal ulcer; Endocrine tumor;
Esophagitis; Gastroesophageal reflux; Helicobacter pylori infection; Stomach ulcer; Zollinger-Ellison syndrome Toxicity: Symptoms of overdose include confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, and dry mouth.